Table 2 Association between GPR155 mRNA expression levels and clinicopathological characteristics of 200 patients with gastric cancer.

Variables	Low GPR155 in GC tissue	High GPR155 in GC tissue	P
Age
<65 years	25	54	0.021
≥65 years	58	63
Sex
Male	66	75	0.017
Female	17	42
CEA (ng/ml)
≤5	62	93	0.426
>5	21	24
CA19-9 (IU/ml)
≤37	60	96	0.103
>37	23	21
Tumor location
Entire	7	12
Upper third	19	25	0.972
Middle third	24	33
Lower third	33	47
Tumor size (mm)
<50	26	47	0.199
≥50	57	70
Macroscopic type
Borrmann type 4/5	9	26	0.033
Others	74	91
Tumor depth (UICC)
pT1-3	47	47	0.021
pT4	36	70
Differentiation
Differentiated	39	35	0.014
Undifferentiated	44	82
Lymphatic involvement
Absent	12	14	0.607
Present	71	103
Vessel invasion
Absent	33	40	0.421
Present	50	77
Infiltrative growth type
Invasive growth	22	56	0.002
Expansive growth	61	61
Lymph node metastasis
Absent	22	35	0.598
Present	61	82
Peritoneal lavage cytology
Negative	65	80	0.118
Positive	18	37
Synchronous hematogenous metastasis
Absent	71	114	0.002
Present	12	3
Synchronous hepatic metastasis
Absent	75	114	0.031
Present	8	3
UICC stage
I	14	18
II	12	21	0.916
III	26	34
IV	31	44
Post-operative chemotherapy (Stage II/III)
S-1 adjuvant	21	29	0.809
None	17	26

^*Statistically significant (P < 0.05). Abbreviations: CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen 19-9; UICC, Union for International Cancer Control.

Quick links

Search